Skip to main content
Clinical Trials/IRCT20230801058996N5
IRCT20230801058996N5
Not yet recruiting
Phase 1

Safety and efficacy of placental mesenchymal stem cells-derived exosomes in severe refractory inflammatory bowel disease patients

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
12
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Ulcerative colitis and/or Crohn's disease for at least 6 months with refractory, or intolerance, or contraindication to use with monoclonal antibodies
  • Highly active Crohn's disease with a Crohn's disease index greater than 450 and/or a simple endoscopic score \= 8 (or \= 6 for isolated intestinal disease)

Exclusion Criteria

  • Using common immunomodulators in the past 4 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials